Full follow-up of the FIBRONEER-IPF trial (1177 patients with IPF): nerandomilast 9 mg and 18 mg did not reduce time to acute exacerbation, respiratory admission or death vs placebo (HR 0.92 and 0.99); death HR 0.66 (0.41-1.08) with 18 mg.
RCTn = 1,177
Oldham et al. Nerandomilast in idiopathic pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-IPF trial